Evaluation of Clindamycinencapsulated in PLA/PLGA nanoparticles

Abstract

Clindamycin hydrochloride (7-chloro-7-deoxylincomycin hydrochloride) is a semi synthetic analogue of a natural antibiotic lincomycin. It is available as white crystalline powder and administered orally. It is commonly used in topical treatment for acne and can be useful against some methicillin-resistant Staphylococcus aureus (MRSA) infections. Various formulations of PLA and PLGA loaded with clindamycin hydrochloride (CLH) nanoparticles were prepared by solvent evaporation method varying the drug concentration to that of polymer concentration (1:20, 1:10 and 1:5) and characterized by using SEM, DSC and FTIR studies. The antimicrobial activity (minimum inhibitory concentration) was tested against two pathogenic bacterial strains. Nanoparticle formulations showed a significant controlled release profile extended up to 144 hrs (both CLH-PLA and CLH-PLGA). The thermal behaviour (DSC) studies of CLH- PLGA nanoparticles confirmed the molecular dispersion of the drug within the system. The FTIR studies confirmed the intactness as well as unaltered structure of drug after conjugation with PLA and PLGA polymers. Therefore, from the above mentioned results we can conclude that by encapsulation of CLH into PLA and PLGA nanoparticles, the various physiochemical properties of the drug increased to satisfactory extent. The drug is more effective at lower concentration against pathogenic microorganisms which can be widely applied in number of therapies.